PPMI Presentations

Select presentations made using PPMI data and specimens are cataloged here. Individuals making PPMI presentations who wish to share them through the website can contact us with information about the presentation for consideration for inclusion.

Displaying 73 presentation(s).
 

 
Title Author(s) Date Meeting/Venue
Cell Line Resources from Parkinson's Progression Markers Initiative (PPMI) Participants T. Ludwig, A. Reimer, T. Foroud, D. Smith, C. Wegel, C. Mitchell, R. Case, M. Frasier, A. Naito, S. Lasch, K. Marek, C. Dunifon 2017-06-14 ISSCR Conference, Boston
Early bilateral caudate involvement in Parkinson’s disease is predictive of cognitive decline Rory Durcan, Louise Wiblin, Morten Gersel Stokholm, Lynn Rochester, David J. Brooks1, David J. Burn, Nicola Pavese 2017-06-06 Vancouer
2017 PPMI Annual Meeting - Day 2, Morning 2017-05-04 New York City
2017 PPMI Annual Meeting - Day 2, Afternoon 2017-05-04 New York City
2017 PPMI Annual Meeting - Day 1, Morning 2017-05-03 New York City
2017 PPMI Annual Meeting - Day 1, Afternoon 2017-05-03 New York City
Structural Brain Alterations Associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease Soufiane Boucetta, Ali Salimi, Mahsa Dadar, Barbara E. Jones, D. Louis Collins & Thien Thanh Dang-Vu 2016-06-01 http://www.nature.com/articles/srep26782
PPMI 2016 Annual Meeting presentations - Day 2 2016-05-04
PPMI 2016 Annual Meeting presentations - Day 1 2016-05-04
Improved Parkinson’s Disease Classification from Diffusion MRI Data by Fisher Vector Descriptors Salamanca, L.; Vlassis, N.; Diederich, N.; Bernard, F.; and Skupin A. 2015-10-05 Munich
Comparison Of Baseline 123?I Ioflupane SPECT Striatal Binding Ratios With Diffusion Tensor Images From The Parkinson's Progression Marker Initiative Gallagher, C.L.; Sojkova, J; Bendlin, B.B.; Okonkwo, O; Alexander, A; Wu, I.W.; Schuff, N 2015-06-14 MDS: San Diego, CA
POSET Based Cognitive Function Impairment (PCFI): A Novel Approach For Delineating Heterogeneity Of Cognitive Impairment In Parkinson's Disease Gupta, D.K.; Goldman, J.G.; Jaeger, J; Tatsuoka, C 2015-06-14 MDS: San Diego, CA
Novel Recruitment Strategy To Enrich For LRRK2 Mutation Carriers Foroud, T; Smith, D; Jackson, J; Verbrugge, J; Halter, C; Wetherill, L; Sims, K; Xin, W; Arnedo, V; Lasch, S; Marek, K 2015-06-14 MDS: San Diego, CA
Incident Impulse Control Disorder Behaviors and Serial Dopamine Transporter Imaging in De Novo Parkinson Disease (Presentation) Smith, K; Xie, S; Weintraub, D 2015-06-14 MDS: San Diego, CA
Olfaction And Nonmotor Symptoms (NMS) In Subjects With Scans Without Evidence Of Dopaminergic Deficit (SWEDDs) Fullard, M.E.; Weintraub, D; Duda, J.E.; Morley, J.F. 2015-06-14 MDS: San Diego, CA
Incident Impulse Control Disorder Behaviors and Serial Dopamine Transporter Imaging in De Novo Parkinson Disease (Poster) Smith, K; Xie, S; Weintraub, D 2015-06-14 MDS: San Diego, CA
2015 PPMI Annual Meeting - Day 2 PPMI Steering Committee & Cores 2015-05-14 PPMI Annual Meeting
2015 PPMI Annual Meeting - Day 1 PPMI Steering Committee & Cores 2015-05-13 PPMI Annual Meeting
Assessment of Parkinson disease progression using 123- I I-Ioflupane SPECT: Update from the Parkinson Progression Marker Initiative Trial Seibyl, J; Jennings, D; Marek, K; the Parkinson's Progression Markers Initiative investigators 2015-04-23 AAN: Washington, DC
Presence of Cerebral Amyloid Modulates Phenotype & Pattern of Neurodegeneration in Early Parkinson’s Disease McMillan, C; Wolk, D 2015-04-22 AAN: Washington, DC
CSF A?1-42 predicts cognitive impairment in de novo PD patients Terrelonge, M; Marder, K; Weintraub, D; Alcalay, R 2015-04-22 AAN: Washington, DC
Objective Measurement of Upper Extremity Motor Function in de novo Parkinson’s Disease Chahine, L; Uribe, L; Hogarth, P; Jennings, D; The Parkinson’s Progression Markers Initiative 2015-04-21 AAN: Washington, DC
Identifying drug-naïve Parkinsonism with Non-motor features & CSF biomarkers: A case-control study Jain, S; Young Park, S; Comer, D; Rudoy, D; Ivanco, L 2015-04-21 AAN: Washington, DC
Using non-motor features to define clinical and biomarker patterns of early drug-naïve Parkinsonism Jain, S; Young Park, S; Comer, D 2015-04-21 AAN: Washington, DC
Non-motor symptoms in early drug-naïve Parkinson’s disease Liu, R; Umbach, D; Peddada, S; Xu, Z; Tröster, A; Huang, X; Chen, H 2015-04-21 AAN: Washington, DC
Early Detection of Parkinson’s Disease Through Shape Based Features From 123I-Ioflupane SPECT Imaging Bhalchandra, N; Prashanth, R; Roy, S; Noronha, S 2015-04-16 International Symposium on Biomedical Imaging: Brooklyn, NY
Longitudinal PD Biomarker Studies: DeNoPa and PPMI Mollenhauer, B 2015-03-22 AD/PD: Nice, France
Progression of White Matter Degeneration in Early Parkinson’s Disease: A Multicenter Evaluation Using Diffusion Tensor Imaging Zhang, Y; Wu, K; Schuff, N; The Parkinson's Progression Markers Initiative 2015-03-21 AD/PD: Nice, France
ACCURATE, NON-INVASIVE AND COST-EFFECTIVE PREDICTIVE MODEL FOR PARKINSON'S DISEASE. Mike A Nalls and Andrew B Singleton on behalf of the Michael J. Fox foundation's Parkinson’s Progression Markers Initiative (PPMI) study, the Parkinson Associated Risk Study (PARS), the NINDS Parkinson's Disease Biomarker Program (PDBP) and the International Parkinson's Disease Genomics Consortium (IPDGC). 2015-03-18 AD/PD: Nice, France
PPMI Progress Update: Available Data and Biosamples Ken Marek and The Michael J. Fox Foundation 2014-12-15 Webinar
Can We Reliably Establish Parkinson's Disease Subtypes In De Novo Patients: Results From The PPMI Study Simuni, T; Caspell-Garcia, C; Coffey, C; Uribe, L; Lasch, S; Jennings, D; Tanner, C; Marek, K; The Parkinson's Progression Markers Initiative 2014-06-12 MDS: Stockholm, Sweden
Excessive Day Time Sleepiness is Not Part of Parkinson's Disease Disability in De Novo Patients: Results from the PPMI Study Simuni, T; Caspell-Garcia, C; Coffey, C; Chahine, L.C; Lasch, S; Oertel, W; Marek, K for the PPMI Sleep Working Group; The Parkinson's Progression Markers Initiative 2014-06-11 MDS: Stockholm, Sweden
PPMI Breakfast Status Update Ken Marek 2014-06-10 MDS: Stockholm, Sweden
Mild Cognitive Impairment and Neuropsychiatric Symptoms in Early, Untreated Parkinson Disease: Results from the PPMI Study Weintraub, D; Simuni, T; Coffey, C; Caspell-Garcia, C; Foster, E; Barone, P; Leverenz, J; Burn, D; Eberling, J; Chahine, L; Litvan, I; Troyer, M; Siderowf, A; Aarsland, D; Hawkins, K; The PPMI Cognitive Behavioral Working Group; The Parkinson's Progression Marker Initiative 2014-06-10 MDS: Stockholm, Sweden
Multicenter Evaluation Of Parkinson's Disease Progression Using 123- I I-Ioflupane SPECT: Update From The Parkinson's Progression Marker Initiative Trial Seibyl, J; Jennings, D; Coffey, C; Marek, K 2014-06-09 MDS: Stockholm, Sweden
The Parkinson's Progression Marker Initiative (PPMI) – Assessment Of Clinical, Imaging And CSF PD Biomarkers The Parkinson's Progression Markers Initiative 2014-06-09 MDS: Stockholm, Sweden
What Do We Now Know About Alpha-Synuclein's Role In Parkinson's Disease Pathology? Trojanowski, J.Q. 2014-06-09 MDS: Stockholm, Sweden
Degeneration of Corticostriatal Fibers in Parkinson’s Disease and their Differential Relations to Cognitive and Motor Deficits Zhang, Y; Wu, K; Buckley, S; Mendick, S; Seibyl, J; Foster, E; Coffey, C; Marek, K; Schuff; N; The Parkinson’s Progression Markers Initiative 2014-06-09 MDS: Stockholm, Sweden
2014 PPMI Annual Meeting - Day 2 PPMI Steering Committee & Cores 2014-05-07 PPMI Annual Meeting
2014 PPMI Annual Meeting - Day 1 PPMI Steering Committee & Cores 2014-05-06 PPMI Annual Meeting
REM Sleep And Motor Symptoms In Parkinson's Disease: A Cross Sectional Analysis Mahajan, A; Rosenthal, L; Gamaldo, C; Salas, R. M; Pontone, G; McCoy, A; Gulyani, S; Umeh, C; Mari, Z 2014-04-29 AAN: Philadelphia, PA
AAN 2014: Differential Patterns Of White Matter Degradation In Relation To Cognitive And Motor Deficits In Parkinson's Disease Zhang, Y; Schuff, N; the Parkinson's Progression Markers Initiative 2014-04-29 AAN: Philadelphia, PA
Developing a Translational Toolbox for Parkinson disease: The Parkinson Progression Marker Initiative Ken Marek 2014-03-04 Keystone Symposia's Parkinson’s Disease: Genetics, Mechanisms, and Therapeutics Conference
PPMI Genetics Kick-Off Meeting - Day 2 PPMI Steering Committee & Cores 2013-09-17 PPMI Genetics Kick-Off Meeting
PPMI Genetics Kick-Off Meeting - Day 1 PPMI Steering Committee & Cores 2013-09-16 PPMI Genetics Kick-Off Meeting
Developing a Translational Toolbox for Parkinson Disease: The Parkinson Progression Marker Initiative Ken Marek 2013-07-13 Alzheimer's Imaging Consortium (AIC): Boston, MA
PPMI Status Update Ken Marek 2013-07-11 World Wide ADNI: Boston, MA
Parkinson's Progression Markers Initiative (PPMI) Trojanowski, J.Q. 2013-06-21 American Association of Neuropathologists (AANP): Charleston, SC
The Parkinson Progression Marker Initiative (PPMI) – Baseline PD, healthy, and SWEDD data Parkinsons Progression Marker Initiative 2013-06-18 MDS: Sydney, Australia
Cognitive performance and psychiatric symptoms in de novo, untreated Parkinson’s disease: results from the PPMI study Weintraub, D; Simuni, T; Coffey, C; Foster, E; Chahine, L; Litvan, I; Troyer, M; Siderowf, A; Hawkins, K; on behalf of the PPMI Cognitive Behavioral Working Group and PPMI Investigators 2013-06-18 MDS: Sydney, Australia
Relationship between Serum Urate and Clinical Features in Early Parkinsons Disease: PPMI Baseline Data Constantinescu, R; Jennings, D; Foster, E.D; Auinger, P; Coffey, C.S; Marerk, K; the Parkinson's Progression Marker Initiative 2013-06-18 MDS: Sydney, Australia
PPMI Breakfast Status Update Ken Marek 2013-06-18 MDS: Sydney, Australia
123-I Ioflupane SPECT Measures of Parkinson Disease Progression in the Parkinson Progression Marker Initiative (PPMI) Trial Seibyl, JP; Jennings, D; Grachev, I; Coffey, C; Marek, KL; on behalf of the PPMI Investigators 2013-06-17 MDS: Sydney, Australia
123-I Ioflupane SPECT Measures of Parkinson Disease Progression in the Parkinson Progression Markers Initiative (PPMI) Trial Seibyl, John; Jennings, Danna; Grachev, Igor D.; Coffey, Christopher; and Marek, Kenneth on behalf of the PPMI Investigators 2013-06-10 Society of Nuclear Medicine and Neuroimaging (SNMMI): Vancouver, Canada
2013 PPMI Annual Meeting - Day 2 PPMI Steering Committee & Cores 2013-05-08 PPMI Annual Meeting
2013 PPMI Annual Meeting - Day 1 PPMI Steering Committee & Cores 2013-05-07 PPMI Annual Meeting
The Parkinson Progression Marker Initiative (PPMI) Ken Marek & PPMI Senior Leadership 2013-03-23 AAN: San Diego, CA
Non-motor Subtypes of Early Parkinson Disease in the Parkinson's Progression Markers Initiative S. Jain; S Young Park 2013-03-22 WFN: San Diego, CA
Feasibility and Safety of Lumbar Punctures in the Parkinson Progression Marker Initiative (PPMI) Samuel Frank, Boston, MA, Shirley Lasch, New Haven, CT, Chelsea Caspell, Iowa City, IA, Liz Uribe, Iowa City, IA, Danna Jennings, New Haven, CT, Kenneth Marek, New Haven, CT, Investigators of Parkinson Progression Markers Initiative, New Haven, CT 2013-03-19 AAN: San Diego, CA
Visualization and Quantification of the Striato-pallidonigral Fibers in Parkinson's Disease Using Diffusion Tensor Imaging Yu Zhang, Katherine Wu, Shannon Buckley, Norbert Schuff 2013-03-07 AD/PD: Florence, Italy
International Conference on Alpha-Synuclein in Parkinson's Disease 2013: Parkinson's Progression Markers Initiative (PPMI) John Q. Trojanowski, M.D., Ph.D. 2013-03-03 International Conference on Alpha-Synuclein in Parkinson's Disease: Dubai, UAE
Association between CSF biomarkers and clinical phenotype of early Parkinson’s disease in the Parkinson’s Progression Marker Initiative (PPMI) Ju-Hee Kang, Chelsea Caspell, Chris Coffey, Peggy Taylor, Mark Frasier, Kenneth Marek, John Q. Trojanowski, Leslie M. Shaw, and the Parkinson’s Progression Marker Initiative 2012-06-17 MDS: Dublin, Ireland
Frequency of Impulse Control Disorder Symptoms in De Novo Parkinson Disease Patients and Healthy Controls Daniel Weintraub, Kimberly Papay, Andrew Siderowf, and the Parkinson's Progression Markers Initiative 2012-06-17 MDS: Dublin, Ireland
Baseline Neuroimaging Characteristics of the Parkinson’s Progression Marker Initiative (PPMI) Parkinsons and Healthy Cohorts J. Seibyl, MD on behalf of the PPMI Investigators 2012-06-17 MDS: Dublin, Ireland
2012 PPMI Annual Meeting PPMI Steering Committee & Cores 2012-05-02 PPMI Annual Meeting
Overview of PPMI Todd Sherer, Sohini Chowdhury, Mark Frasier, Jamie Eberling, Bernard Ravina, Andrew Siderowf, Clemens Scherzer, Danna Jennings, Caroline Tanner, Karl Kieburtz, Brit Mollenhauer, John Seibyl, Christopher Coffey, Arthur Toga, Leslie Shaw, John Q. Trojanowski, and Ken Marek 2011-05-15 Society for Clinical Trials: Vancouver, Canada
2011 PPMI Annual Meeting PPMI Steering Committee & Cores 2011-05-05 PPMI Annual Meeting
Clinical Site Training on Biologics Alison Ansbach, MS and Mark Frasier, PhD 2010-11-01 Webinar
PD Therapeutics Conference: Update on PPMI Ken Marek 2010-10-07 PD Therapeutics Conference
Clinical Site Training on Cognitive Assessments Andrew Siderowf, MD 2010-06-25 Webinar
Introduction to PPMI M Frasier, S Chowdhury, T Sherer , J Eberling, C Meunier, B Ravina, A Siderowf, C Scherzer, D Jennings, C Tanner, K Kieburtz, C Coffey, W Poewe, B Mollenhauer, J Seibyl, A Toga, A Ansbach, P De Blasio, M Piovella, J Trojanowski, L Shaw, A Singleton, and K Marek 2010-06-17 MDS: Buenos Aries, Argentina
2010 Investigators Meeting Slides PPMI Steering Committee & Presenters 2010-03-12 PPMI Annual Meeting
PPMI 2017 Annual Meeting Agenda 0000-00-00